Impairment of axonal transport leads to neurodegeneration and synapse loss. Glutamate and amyloid β-protein (Aβ) have critical roles in the pathogenesis of Alzheimer's disease (AD). Here we show that both agents rapidly inhibit fast axonal transport in cultured rat hippocampal neurons. The effect of glutamate (100 μ m ), but not of Aβ 25-35 (20 μ m ), was reversible, was mimicked by NMDA or AMPA, and was blocked by NMDA and AMPA antagonists and by removal of extracellular Ca 2+ . The effect of Aβ 25-35 was progressive and irreversible, was prevented by the actin-depolymerizing agent latrunculin B, and was mimicked by the actin-polymerizing agent jasplakinolide. Aβ 25-35 induced intracellular actin aggregation, which was prevented by latrunculin B. Aβ 31-35 but not Aβ 15-20 exerted effects similar to those of Aβ 25-35 . Full-length Aβ 1-42 incubated for 7 d, which specifically contained 30-100 kDa molecular weight assemblies, also caused an inhibition of axonal transport associated with intracellular actin aggregation, whereas freshly dissolved Aβ 1-40 , incubated Aβ 1-40 , and fresh Aβ 1-42 had no effect. These results suggest that glutamate inhibits axonal transport via activation of NMDA and AMPA receptors and Ca 2+ influx, whereas Aβ exerts its inhibitory effect via actin polymerization and aggregation. The ability of Aβ to inhibit axonal transport seems to require active amino acid residues, which is probably present in the 31-35 sequence. Full-length Aβ may be effective when it represents a structure in which these active residues can access the cell membrane. Our results may provide insight into the early pathogenetic mechanisms of AD.
No takes yet. Share an insight, caveat, or question.
Hiruma et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: